Clinical use of nifedipine GITS in the treatment of hypertension: An overview

Expert Opinion on Pharmacotherapy

Volumn 4, Issue 1, 2003, Pages 95-106

  Simon, Alain ^a   Levenson, Jaime ^a  

^a HÔPITAL BROUSSAIS   (France)

Author keywords

Dihydropyridine calcium channel blocker; Hypertension; Nifedipine GITS

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMILORIDE PLUS HYDROCHLOROTHIAZIDE; AMLODIPINE; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CERIVASTATIN; CHLORTALIDONE; CIMETIDINE; COAMILOZIDE; CYTOCHROME P450 3A4; DIGOXIN; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; FELODIPINE; HYDROCHLOROTHIAZIDE; ISRADIPINE; LISINOPRIL; NIFEDIPINE; NIFEDIPINE GITS; NITRENDIPINE; PLACEBO; PROPRANOLOL; QUINIDINE; THIAZIDE DIURETIC AGENT; UNCLASSIFIED DRUG; UNINDEXED DRUG; VERAPAMIL;

AGE; AGED; ATHEROSCLEROSIS; BLOOD PRESSURE REGULATION; CAROTID ARTERY DISEASE; CLINICAL TRIAL; COMORBIDITY; CORONARY ARTERY ATHEROSCLEROSIS; DEPRESSION; DIABETES MELLITUS; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG INDICATION; DRUG METABOLISM; DRUG RESPONSE; DRUG STRUCTURE; DRUG TOLERABILITY; FOOD DRUG INTERACTION; GENERAL PRACTITIONER; GOUT; HEADACHE; HEART INFARCTION; HEART PALPITATION; HUMAN; HYPERTENSION; HYPOKALEMIA; IMPOTENCE; ISCHEMIC HEART DISEASE; METABOLIC DISORDER; MORBIDITY; MORTALITY; NEGRO; PERIPHERAL EDEMA; PERIPHERAL VASCULAR DISEASE; POLYPHARMACY; POPULATION; PREVALENCE; PUBLIC HEALTH; REVIEW; RISK FACTOR; SLOW RELEASE FORMULATION; STROKE; SYSTOLIC HYPERTENSION;

DELAYED-ACTION PREPARATIONS; HUMANS; HYPERTENSION; NIFEDIPINE;

EID: 0037243759     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.4.1.95     Document Type: Review

References (79)

1. UEMURA K, PISA Z: Trends in cardiovascular disease mortality in industrialized countries since 1950. World Health Stat. Q. (1988) 41(3-4):155-178.
2. JOFFRES MR, HAMET P, MACLEAN DR, L'ITALIEN GJ, FODOR G: Distribution of blood pressure and hypertension in Canada and the United States. Am. J. Hypertens. (2001) 14(11):1099-1105.
3. MARQUES-VIDAL P, TUOMILEHTO J: Hypertension awareness, treatment and control in the community. is the 'rule of halves'still valid? J. Hum. Hypertens. (1997) 11(4):213-220.
4. PRIMATESTA P, BROOKES M, POULTER NR: Improved hypertension management and control: results from the health survey for England 1998. Hypertension (2001) 38(4):827-832.
5. MURRAY CJL, LOPEZ AD (Eds): The Global Burden of Disease. A comprehensive assessment of mortality and disability from diseases, injuries, and risk factors in 1990 and projected to 2020. World Health Organization, Harvard University Press, (1996).
6. The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch. Intern. Med. (1997) 157(21):2413-2446.
7. MACMAHON S, PETO R, CUTLER J et al.: Blood pressure, stroke, and coronary heart disease. Part 1. Prolonged differences in blood pressure. prospective observational studies corrected for the regression dilution bias. Lancet (1990) 335(8692):765-774.
8. FLACK JM, NEATON J, GRIMM R Jr et al.: Blood pressure and mortality among men with prior myocardial infarction. Multiple Risk Factor Intervention Trial Research Group. Circulation (1995) 92(9):2437-2445.
9. CRUICKSHANK JM, THORP JM, ZACHARIAS FJ: Benefits and potential harm of lowering high blood Pressure. Lancet (1987) 1(8533):581-584.
10. US RENAL DATA SYSTEM: USRDS 1997 Annual Report. National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, USA (1997).
11. ABBOTT RD, DONAHUE RP, MACMAHON SW, REED DM, YANO K: Diabetes and the risk of stroke. The Honolulu Heart Program. JAMA (1987) 257(7):949-952.
12. STAMLER J, VACCARO O, NEATON JD, WENTWORTH D: Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diab. Care (1993) 16(2):434-444.
13. CHALMERS J, MACMAHON S, MANCIA G et al.: 1999 World Health Organization-Internationl Society of Hypertension Guidelines for the management of hypertension. Guidelines sub-committee of the World Health Organization. Clin. Exp. Hypertens. (1999) 21(5-6):1009-1060.
14. RAMSAY L, WILLIAMS B, JOHNSTON G et al.: Guidelines for management of hypertension: report of the third working party of the British Hypertension Society. J. Hum. Hypertens. (1999) 13(9):569-592.
15. STAESSEN JA, FAGARD R, THIJS L et al.: Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet (1997) 350(9080):757-764.
16. MANDAL AK: Profiling Antihypertensive Therapy. Am. J. Ther. (1995) 2(7):509-517.
17. HOCKERMAN GH, PETERSON BZ, JOHNSON BD, CATTERALL WA: Molecular determinants of drug binding and action on L-type calcium channels. Annu. Rev. Pharmacol. Toxicol. (1997) 37:361-396.
18. ABERNETHY DR, SCHWARTZ JB: Calcium-antagonist drugs. N. Engl. J. Med. (1999) 341(19):1447-1457.
19. LEVENSON JA, SAFAR ME, SIMON AC, BOUTIER JA, GRIENER L: Systemic and arterial hemodynamic effects of nifedipine (20 mg) in mild-to-moderate hypertension. Hypertension (1983) 5(6):V57-V60.
20. HILLEMAN DE, MOHIUDDIN SM, LUCAS BD Jr, SHINN B, ELSASSER GN: Conversion from sustained-release to immediate-release calcium entry blockers: outcome in patients with mild-to-moderate hypertension. Clin. Ther. (1993) 15(6):1002-1010.
21. MOHIUDDIN SM, HILLEMAN DE: Substituting nifedipine-GITS for immediate-release calcium-channel antagonists in patients with stable angina pectoris, Curr. Ther. Res. (1991) 50:546-552.
22. MYERS MG, TANNER J, LEENEN FHH: Comparative efficacy of two long-acting formulations of nifedipine in the treatment of hypertension. Am. J. Hypertens. (1994) 7:45A.
23. SWANSON DR. BARCLAY BL, WONG PS, THEEUWES F: Nifedipine gastrointestinal therapeutic system. Am. J. Med. (1987) 83(6B):3-9.
24. CHUNG M, REITBERG DP, GAFFNEY M, SINGLETON W: Clinical pharmacokinetics of nifedipine gastrointestinal therapeutic system. A controlled-release formulation of nifedipine. Am. J. Med. (1987) 83(6B):10-14.
25. CROME P, MUELLER FO, WIJAYAWARDHANA P et al.: Single dose and steady-state pharmacokinetic profiles of nifedipine GITS tablet in healthy elderly and young volunteers. Drug Invest. (1993) 5(4):193-199.
26. RAEMSCH KD, SOMMER J: Pharmacokinetics and metabolism of nifedipine. Hypertension (1983) 5(Suppl. II):18-24.
27. SCHNEIDER R, STOLERO D, GRIFFEL L, KOBELT R, BRENDEL E, IAINA A: Pharmacokinetic profile of nifedipine GITS in hypertensive patients with chronic renal impairment. Drugs (1994) 48(Suppl. 1):16-21; discussion 21-22.
28. GUENGERICH FP, MARTIN MV, BEAUNE PH, KREMERS P, WOLFF T, WAXMAN DJ: Characterization of rat and human liver microsomal cytochrome P-450 form involved in nifedipine oxidation, a prototype for generic polymorphism in oxidative drug metabolism. J. Biol. Chem. (1986) 261(11):5051-5060.
29. BRAVO EL, KRAKOFF LR, TUCK ML, FRIEDMAN CP: Antihypertensive effectiveness of nifedipine gastrointestinal therapeutic system in the elderly. The Modern Approach to the Treatment of Hypertension (MATH) Study Group. Am. J. Hypertens. (1990) 3(12):326S-332S.
30. KRAKOFF LR: Effectiveness of nifedipine gastrointestinal therapeutic system for treatment of hypertension: results of the MATH Trial. J. Cardiovasc. Pharmacol. (1993) 21(Suppl. 2):S14-S17.
31. KRAKOFF LR, BRAVO EL, TUCK ML et al.: Comparison of the effects of nifedipine gastrointestinal therapeutic system in black and white essential hypertensives.J. Hum. Hypertens. (1990) 4:765.
32. ZANCHETTI A: Trough:peak ratio of the blood pressure response to dihydropyridine calcium antagonists. Italian Nifedipine GITS Study Group. J. Hypertens. Suppl. (1994) 12(8):S97-S106.
33. GEIZHALS M, PHILLIPS RA, ARDELJAN M, KRAKOFF LR: Sustained calcium channel blockade in the treatment of severe hypertension. A two year experience. Am. J. Hypertens. (1990) 3(12):313S-317S.
34. FAGAN TC, HAGGERT BE: Extended release felodipine and nifedipine are equivalent in treatment of stage II-III hypertension Am. J. Hypertens. (1994) 7:39A.
35. LEVY B, ROSENBERG L, COLASANTE D: A comparison of two structurally distinct types of calcium channel blockers in the treatment of patients with mild to moderate hypertension. Drug Invest. (1993) 5:289-295.
36. ST JOHN HAMMOND PG, PLESKOW W, PLESKOW S: Once-a day antihypertensive therapy: comparison of extended-release diltiazem HCl and extended-release nifedipine. Cardiovasc. Rev. Rep. (1994) (July):46-58.
37. FRISHMAN WH, GAROFALO JL, ROTHSCHILD A, ROTHSCHILD M, GREENBERG SM, SOBERMAN J: Multicenter comparison of the nifedipine gastrointestinal therapeutic system and long-acting propranolol in patients with mild to moderate systemic hypertension receiving diuretics. A preliminary experience. Am. J. Med. (1987) 83(6B):15-19.
38. HOUSTON MC, OLAFSSON L, BURGER MC: Effects of nifedipine GITS and atenolol monotherapy on serum lipids, blood pressure, heart rate, and weight in mild to moderate hypertension. Angiology (1991) 42(9):681-690.
39. FRIEDMAN NDA, WILSON A: Efficacy of lisinopril and nifedipine GITS in hypertension asoociated with non-insulin dependent diabetes. Diabetes (1994) 43(Suppl. I):59.
40. LEON AS: Efficacy and safety of enalapril versus extended-release nifedipine for the treatment of mild-to-moderate essential hypertension: a multicenter 22-week study. Multicenter Cooperative Study Group. Clin. Ther. (1993) 15(6):1094-1107.
41. MANCIA G, OMBONI S, PARATI G: Twenty-four hour ambulatory blood pressure in the International Nifedipine GITS Study Intervention as a Goal in Hypertension Treatment (INSIGHT). J. Hypertens. (2002) 20(3):545-553.
42. TESTA MA, HOLLENBERG NK, ANDERSON RB, WILLIAMS GH: Assessment of quality of life by patient and spouse during antihypertensive therapy with atenolol and nifedipine gastrointestinal therapeutic system. Am. J. Hypertens. (1991) 4(4):363-373.
43. PHILLIPS RA, ARDELJAN M, SHIMABUKURO S et al.: Effect of nifedipine GITS on left ventricular mass and diastolic function in severe hypertension J. Cardiovasc. Pharmacol. (1991) 17(Suppl. 2):S172-S174.
44. PHILLIPS RA, ARDELJAN M, SHIMABUKURO S et al.: Effects of nifedipine-GITS on left ventricular mass and left ventricular filling. J. Cardiovasc. Pharmacol. (1992) 19(Suppl. 2):S28-S34.
45. ZUSMAN RM, CHRISTENSEN DM, HIGGINS J, BOUCHER CA: Nifedipine improves left ventricular function in patients with hypertension. J. Cardiovasc. Pharmacol. (1991) 18(6):843-848.
46. SCHNACK C, CAPEK M, BANYAI M, KAUTZKY-WILLER A, PRAGER R, SCHERNTHANER G: Long-term treatment with nifedipine reduces urinary albumin excretion and glomerular filtration rate in normotensive type 1 diabetic patients with microalbuminuria. Acta Diabetol. (1994) 31(1):14-18.
47. DEQUATTRO V, LI D, LU ZH: Improved early morning blood pressure control with nifedipine GITS versus enalapirl (once a day) despite equivalency in reduction for proteinuria in elderly hypertensives. Can J. Physiol. Pharmacol. (1994) 72(Suppl. 1):135.
48. GONG L, ZHANG W, ZHU Y et al.: Shanghai trial of nifedipine in the elderly (STONE). J. Hypertens. (1996) 14(10):1237-1245.
49. LIU L, WANG JG, GONG L, LIU G, STAESSEN JA: Comparison of active treatment and placebo in older Chinese patients with isolated systolic hypertension. Systolic Hypertension in China (Syst-China) Collaborative-Group. J. Hypertens. (1998) 16(12):1823-1829.
50. TUOMILEHTO J, RASTENYTE D, BIRKENHAGER WH et al: Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. Systolic Hypertension in Europe Trial Investigators. N. Engl. J. Med. (1999) 340(9):677-684.
51. WANG JG, STAESSEN JA. GONG L, LIU L: Chinese trial on isolated systolic hypertension in the elderly. Systolic Hypertension in China (Syst-China) Collaborative Group. Arch. Intern. Med. (2000) 160(2):211-220.
52. BROWN MJ, PALMER CR, CASTAIGNE, A et al.: Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet (2000) 356(9227):366-372.
53. COLLINS R, MACMAHON S: Blood pressure, antihypertensive drug treatment and the risks of stroke and of coronary heart disease Br. Med. Bull. (1994) 50(2):272-298.
54. MANCIA G. RUILOPE LM, BROWN MJ et al.: The effect of nifedipine GITS on outcomes in patients with previous myocardial infarction: a subgroup analysis of the INSIGHT study. Br. J. Cardiol. (2002) 9(7):401-405.
55. MOTRO M, SHEMESH J: Calcium channel blocker nifedipine slows down progression of coronary calcification in hypertensive patients compared with diuretics. Hypertension (2001) 37(6):1410-1413.
56. SIMON A. GARIEPY J, MOYSE D, LEVENSON J: Differential effects of nifedipine and co-amilozide on the progression of early carotid wall changes. Circulation (2001) 103(24):2949-2954.
57. LÜSCHER TF, VANHOUTTE PM: The endothelium: modulator of cardiovascular function. CRC Press, Boca Raton (1990).
58. TSCHUDI MR, CRISCIONE L, NOVOSEL D, PFEIFFER K, LUSCHER TF: Antihypertensive therapy augments endothelium-dependent relaxations in coronary arteries of spontaneously hypertensive rats. Circulation (1994) 89(5):2212-2218.
59. LUESCHER TF, ZEIHER AM, MEINERTZ T et al.: Effects of calcium antagonism and HMG co-enzyme reductase inhibition on endothelial function and atherosclerosis: rationale and outline of the ENCORE trials. J. Cardiovasc. Pharmacol. (1997) 30(Suppl. 3):S48-S52.
60. LUBSEN J, POOLE-WILSON PA: ACTION: a 30,000 patient-years double-blind, placebo-controlled trial of nifedipine GITS in stable angina. ACTION Research Group. Br. J. Clin. Pract. Suppl. (1997) 88:23-26.
61. TOAL CB: Efficacy of a low dose nifedipine ITS (20 mg) in patients with mild to moderate hypertension. Can. J. Cardiol. (1997) 13(10):921-927.
62. HELD PH, YUSUF S, FURBERG CD: Calcium channel blockers in, acute myocardial infarction and unstable angina: an overview. BMJ (1989) 299(6709):1187-1192.
63. YUSUF S, HELD P, FURBERG C: Update of effects of calcium antagonists in myocardial infarction or angina in light of the second Danish Verapamil Infarction Trial (DAVIT-II) and other recent studies. Am. J. Cardiol. (1991) 67(15):1295-1297.
64. Effects of calcium antagonists on the risks of coronary heart disease, cancer and bleeding. Ad Hoc Subcommittee of the Liaison Committee of the World Health Organisation and the Intertational Society of Hypertension. J. Hypertens. (1997) 15(2):105-115.
65. NEAL B, MACMAHON S, CHAPMAN N: Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists' Collaboration. Lancet (2000) 356(9246):1955-1964.
66. CUTLER JA: Calcium-channel blockers for hypertension-uncertainty continues. N. Engl. J. Med. (1998) 338(10):679-681.
67. PAHOR M, GURALNIK JM, CORTI MC, FOLEY DJ, CARBONIN P, HAVLIK RJ: Long-term survival and use of antihypertensive medications in older persons. J. Am. Geriatr. Soc. (1995) 43(11):1191-1197.
68. PAHOR M, GURALNIK JM, FERRUCCI L et al.: Calcium-channel blockade and incidence of cancer in aged populations. Lancet (1996) 348(9026):493-497.
69. PAHOR M, GURALNIK JM, FURBERG CD, CARBONIN P, HAVLIK R: Risk of gastrointestinal haemorrhage with calcium antagonists in hypertensive persons over 67 years old. Lancet (1996) 347(9008):1061-1065.
70. PAHOR M, GURALNIK JM, SALIVE ME, CORTI MC, CARBONIN P, HAVLIK RJ: Do calcium channel blockers increase the risk of cancer? Am. J. Hypertens. (1996) 9(7):695-699.
71. PAHOR M, MANTO A, PEDONE C, CAROSELLA L, GURALNIK JM, CARBONIN P: Age and severe adverse drug reactions caused by nifedipine and verapamil. Gruppo Italiano di Farmacovigilanza nell' Anziano (GIFA). J. Clin. Epidemiol. (1996) 49(8):921-928.
72. STANTON AV: Calcium channel blockers. The jury is still out on whether they cause heart attacks and suicide. BMJ (1998) 316(7143):1471-1473.
73. FURBERG CD, PSATY BM: Should calcium antagonists be first-line agents in the treatment of cardiovascular disease? The public health perspective. Cardiovasc. Drugs Ther. (1996) 10(4):463-466.
74. PAHOR M, PSATY BM, ALDERMAN MH et al.: Health outcomes associated with calcium antagonists compared with other first-line antihypertensive therapies: a meta-analysis of randomised controlled trials. Lancet (2000) 356(9246):1949-1954.
75. HANSSON L, HEDNER T, LUND-JOHANSEN P et al.: Randomised trial of effects of calcium antagonists compared with diuretics and β-blockers on cardiovascular morbidity and mortality in hypertension. the Nordic Diltiazem (NORDIL) study. Lancet (2000) 356(9227):359-365.
76. HANSSON L, LINDHOLM LH, EKBOM T et al.: Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. Lancet (1999) 354(9192):1751-1756.
77. SCHUG BS, BRENDEL E, CHANTRAINE E et al.: The effect of food on the pharmacokinetics of nifedipine in two slow release formulations: pronounced lag-time after a high fat breakfast Br. J. Clin. Pharmacol. (2002) 53(6):582-588.
78. BORHANI NO, MERCURI M, BORHANI PA et al.: Final outcome results of the Multicenter Isradipine Diuretic Atherosclerosis Study (MIDAS). A randomized controlled trial. JAMA (1996) 276(10):785-791.
79. ZANCHETTI A, ROSEI EA, DAL PALU C, LEONETTI G, MAGNANI B, PESSINA A: The Verapamil in Hypertension and Atherosclerosis Study (VHAS): results of long-term randomized treatment with either verapamil or chlorthalidone on carotid intima-media thickness. J. Hypertens. (1998) 16(11):1667-1676.